Back to Search
Start Over
Expert Consensus Statements on the Use of Corticosteroids in Non-severe COVID-19
- Source :
- Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine
- Publication Year :
- 2021
- Publisher :
- Jaypee Brothers Medical Publishers, 2021.
-
Abstract
- Introduction There is strong evidence for the use of corticosteroid in the management of severe coronavirus disease-2019 (COVID-19). However, there is still uncertainty about the timing of corticosteroids. We undertook a modified Delphi study to develop expert consensus statements on the early identification of a subset of patients from non-severe COVID-19 who may benefit from using corticosteroids. Methods A modified Delphi was conducted with two anonymous surveys between April 30, 2021, and May 3, 2021. An expert panel of 35 experts was selected and invited to participate through e-mail. The consensus was defined as >70% votes in multiple-choice questions (MCQ) on Likert-scale type statements, while strong consensus as >90% votes in MCQ or >50% votes for “very important” on Likert-scale questions in the final round. Results Twenty experts completed two rounds of the survey. There was strong consensus for the increased work of breathing (95%), a positive six-minute walk test (90%), thorax computed tomography severity score of >14/25 (85%), new-onset organ dysfunction (using clinical or biochemical criteria) (80%), and C-reactive protein >5 times the upper limit of normal (70%) as the criteria for patients’ selection. The experts recommended using oral or intravenous (IV) low-dose corticosteroids (the equivalent of 6 mg/day dexamethasone) for 5–10 days and monitoring of oxygen saturation, body temperature, clinical scoring system, blood sugar, and inflammatory markers for any “red-flag” signs. Conclusion The experts recommended against indiscriminate use of corticosteroids in mild to moderate COVID-19 without the signs of clinical worsening. Oral or IV low-dose corticosteroids (the equivalent of 6 mg/day dexamethasone) for 5–10 days are recommended for patients with features of disease progression based on clinical, biochemical, or radiological criteria after 5 days from symptom onset under close monitoring. How to cite this article How to cite this article: Nasa P, Chaudhry D, Govil D, Daga MK, Jain R, Chhallani AA, et al. Expert Consensus Statements on the Use of Corticosteroids in Non-severe COVID-19. Indian J Crit Care Med 2021;25(11):1280–1285.
- Subjects :
- Thorax
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
business.industry
medicine.drug_class
Non-severe COVID-19
SARS-CoV-2
education
Organ dysfunction
Delphi method
Consensus Statement
Corticosteroids in moderate COVID-19
Critical Care and Intensive Care Medicine
Delphi study
Work of breathing
Radiological weapon
Internal medicine
Medicine
Corticosteroid
medicine.symptom
business
Dexamethasone
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 1998359X and 09725229
- Volume :
- 25
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine
- Accession number :
- edsair.doi.dedup.....472ece679f4ff9b547fa057ab7f67f05